Accelerating drug discovery through AI fusion
An in-silico research-use-only (RUO) framework designed to accelerate drug discovery by fusing the capabilities of discriminative and generative Artificial Intelligence. Our platform orchestrates a generalist genome foundation model with a suite of specialist predictors and structural oracles to achieve state-of-the-art performance across multiple benchmarks.
Identifies viral sequences and prophage regions
Predicts protein structure from 1D sequences
Precise CRISPR guide RNA design and optimization
Cross-species biological understanding
Complete RUO workflow combining discriminative and generative AI for therapeutic discovery, from problem framing to validated designs ready for wet-lab validation.
Assemble genomic loci, clinical variants, DMS datasets, and assay priors
Score disease-relevant variants with CrisPRO.ai ΔLL and specialist ensemble
Use CrisPRO.ai embeddings for exon/intron features and region ranking
CrisPRO.ai sequence proposals with epigenomic guidance and structural validation
Aggregate scores and prioritize designs for wet-lab validation
Fit supervised heads and calibrate by cohort for continuous improvement
Generate evidence reports with traceable citations and audit trails
Our results demonstrate that this fusion approach achieves 95.7% AUROC ClinVar validation on 53,210 samples, resolves 73% of Variants of Uncertain Significance (VUS), and provides a comprehensive, transparent, and controllable system for in-silico drug discovery.
Accelerate R&D from years to weeks
Reduce experimental costs by $2.1M per program
Transform 40% VUS rate to 15% with validated predictions
Enable precision therapeutic design with predictable quality scaling
Provide comprehensive, transparent, and controllable system
Reduce experimental costs by $2.1M per program